BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38534929)

  • 1. Does Pre-Emptive Availability of PREDICT 2.1 Results Change Ordering Practices for Oncotype DX? A Multi-Center Prospective Cohort Study.
    Awan AA; Saunders D; Pond G; Hamm C; Califaretti N; Mates M; Kumar V; Ibrahim MFK; Beltran-Bless AA; Vandermeer L; Hilton J; Clemons M
    Curr Oncol; 2024 Feb; 31(3):1278-1290. PubMed ID: 38534929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Genomic Assay Testing and Clinical Factors on Chemotherapy Use After Implementation of Standardized Testing Criteria.
    Natsuhara KH; Losk K; King TA; Lin NU; Camuso K; Golshan M; Pochebit S; Brock JE; Bunnell CA; Freedman RA
    Oncologist; 2019 May; 24(5):595-602. PubMed ID: 30076279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does integration of Magee equations into routine clinical practice affect whether oncologists order the Oncotype DX test? A prospective randomized trial.
    Robertson SJ; Ibrahim MFK; Stober C; Hilton J; Kos Z; Mazzarello S; Ramsay T; Fergusson D; Vandermeer L; Mallick R; Arnaout A; Dent SF; Segal R; Sehdev S; Gertler S; Hutton B; Clemons M
    J Eval Clin Pract; 2019 Apr; 25(2):196-204. PubMed ID: 30672056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors influencing Oncotype DX use in the management of early breast cancer: a single centre experience.
    Zhu X; Dent S; Paquet L; Zhang T; Graham N; Song X
    Eur J Cancer; 2014 Oct; 50(15):2544-9. PubMed ID: 25129366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre.
    McVeigh TP; Hughes LM; Miller N; Sheehan M; Keane M; Sweeney KJ; Kerin MJ
    Eur J Cancer; 2014 Nov; 50(16):2763-70. PubMed ID: 25240289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncotype DX
    Rath MG; Uhlmann L; Fiedler M; Heil J; Golatta M; Dinkic C; Hennigs A; Schott S; Ernst V; Koch T; Sohn C; Brucker C; Rom J
    Arch Gynecol Obstet; 2018 Feb; 297(2):443-447. PubMed ID: 29236174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of PONDx, a prospective multicenter study of the Oncotype DX
    Curtit E; Vannetzel JM; Darmon JC; Roche S; Bourgeois H; Dewas S; Catala S; Mereb E; Fanget CF; Genet D; Forest AM; Bernier C; Pivot X
    Breast; 2019 Apr; 44():39-45. PubMed ID: 30634106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands.
    Simons MJHG; Machielsen PM; Spoorendonk JA; Ignacio T; Drost PB; Jacobs T; de Jongh FE
    J Med Econ; 2024; 27(1):445-454. PubMed ID: 38436289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score?
    Auerbach J; Kim M; Fineberg S
    Arch Pathol Lab Med; 2010 Nov; 134(11):1697-701. PubMed ID: 21043825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Oncotype Dx Assay in ER-Positive, HER2-Negative Breast Cancer Patients: A Real Life Experience from a Single Cancer Center.
    Thibodeau S; Voutsadakis IA
    Eur J Breast Health; 2019 Jul; 15(3):163-170. PubMed ID: 31312792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of Oncotype Dx recurrence score using clinical parameters: A comparison of available tools and a simple predictor based on grade and progesterone receptor.
    Thibodeau S; Voutsadakis IA
    Hematol Oncol Stem Cell Ther; 2019 Jun; 12(2):89-96. PubMed ID: 30796885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
    Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline.
    Blanchette P; Sivajohanathan D; Bartlett J; Eisen A; Feilotter H; Pezo R; Turashvili G; Williams P
    Curr Oncol; 2022 Apr; 29(4):2599-2615. PubMed ID: 35448187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
    Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
    Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is the oncotype DX test useful in elderly breast cancer patients: a subgroup analysis of real-life Italian PONDx study.
    Barni S; Cognetti F; Petrelli F
    Breast Cancer Res Treat; 2022 Jan; 191(2):477-480. PubMed ID: 34817748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of Oncotype Dx score with tumor grade, size, nodal status, proliferative marker Ki67 and Nottingham Prognostic Index in early breast cancer tumors in Saudi Population.
    Durrani S; Al-Mushawa F; Heena H; Wani T; Al-Qahtani A
    Ann Diagn Pathol; 2021 Apr; 51():151674. PubMed ID: 33360027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial experience with the Oncotype DX assay in decision-making for adjuvant therapy of early oestrogen receptor-positive breast cancer in Hong Kong.
    Cheung PS; Tong AC; Leung RC; Kwan WH; Yau TC
    Hong Kong Med J; 2014 Oct; 20(5):401-6. PubMed ID: 24948666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the role of pharmacy technicians in reviewing the eligibility for Oncotype DX genomic test and the impact of the test on treatment plans in breast cancer patients.
    Cheng V; Markarian A; de Lemos ML; Schaff K
    J Oncol Pharm Pract; 2019 Jul; 25(5):1167-1173. PubMed ID: 30348071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group*
    Genet Med; 2016 Aug; 18(8):770-9. PubMed ID: 26681310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.